PLUR
NASDAQ
$1.82
Pluri Inc (PLUR)
Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy, utilizing its proprietary technology platform to develop advanced cell-based therapies for oncology and degenerative conditions. With a robust pipeline of therapeutics aimed at addressing critical unmet medical needs, Pluri actively forms strategic collaborations that bolster its research and development capabilities. Committed to revolutionizing patient care, Pluri is well-positioned to become a significant contributor in the biotechnology landscape, driving growth and delivering impactful healthcare solutions.
Sector:
Healthcare
Industry:
Biotechnology
Target: $12 (+559.34%)
Market Cap
$18M
Revenue 5Y CAGR
+115.90%
Beta (5Y)
0.04
Price Chart
Valuation
Market Cap$18M
Forward P/E3.63
P/S17.50
P/B306.56
Profitability
Total Revenue (TTM)$1.08M
Gross Profit (TTM)$464K
EBITDA-$26M
Operating Margin-3914%
EPS-$2.87
Growth & Risk
EPS 5Y CAGR-24.16%
Revenue 5Y CAGR+115.90%
FCF 5Y CAGR-5.03%
Beta (5Y)0.04
Sharpe Ratio-1.20